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Electroanalysis of Benzalkonium Chloride in Ophthalmic
Formulation by Boron-doped Diamond Electrode
Huda Alghamdi,[a] Majidah Alsaeedi,[a] Alyah Buzid,[b] Jeremy D. Glennon,*[a] and John H. T. Luong*[a]
Abstract: Benzalkonium chloride (BAK) is a mixture of
alkyl benzyl dimethyl ammonium chlorides, which is used
primarily as a biocide, surfactant, preservative, and
antimicrobial agent in the pharmaceutical industry, in
particular in ophthalmologic and nasal solutions. How-
ever, BAK may cause harmful consequences on the eye
structures of the anterior segment. Control of BAK
identity and content is necessary by applying a sensitive
detection method. This study unravels the use of a glassy
carbon (GC) electrode and a pristine boron-doped
diamond electrode (BDD) for the detection of four BAK
homologs in a non-aqueous medium using square wave
voltammetry (SWV). The BDD provided more reproduci-
bility of the oxidation potential than GC with a correla-
tion coefficient of 0.999. The irreversible oxidation peak
was very broad and deconvoluted into 3 peaks corre-
sponding to C12, C14, and combined C16–C18 to reflect their
concentration ratio in the mixture. The method was then
extended to the detection of the C12 homolog in the
ophthalmic formulations with a limit of detection (LOD)
of 0.4 μg/mL. The estimated BAK levels in three
ophthalmic formulations were in agreement with the
specified values by the manufacturers. The results were
validated by high-performance liquid chromatography
(HPLC) with ultraviolet (UV) detection, confirming the
presence of a single homolog (C12) in the eye drops.
Keywords: Benzalkonium chloride · electrochemical method · boron-doped diamond electrode · C12 homologs · high-performance
liquid chromatography · eye drops
1 Introduction
Benzalkonium chloride (BAK, C6H5CH2N
+(CH3)2R] Cl
  )
consists of a mixture of alkyl benzyl dimethylammonium
chlorides, where R represents n-C8H17 to n-C18H37. The
four most important homologs are C12, C14, C16, and C18,
cationic surfactants which serve as biocides, and phase
transfer agents [1]. BAK is often used as a disinfectant,
preservative, and antibacterial agent in the pharmaceut-
ical industry [2]. It also serves as fungicides, spermicides,
and virucides [3] with antiviral activities against some
enveloped and non-enveloped viruses [3b,4]. Besides
bacteria, the C12 homolog is most effective against fungi
and yeast, whereas the C14 and C16 homologs display
antimicrobial activities against bacteria (Gram-negative
and Gram-positive) [2b,5]. The bactericidal activity of
BAK (1 mg/mL) can be attributed to the inactivation of
bacterial energy-producing enzymes, denaturation of
essential proteins, and disruption of the bacterial mem-
brane [6]. The BAK homologs are formulated in pharma-
ceutical and industrial products below toxicity levels
(200 mg/kg), otherwise, it induces toxicity in animals, the
environment, and humans [3a, 6–7]. Besides the damage
of human nose epithelia and exacerbation of rhinitis [8],
BAK has been associated with ocular adverse effects,
including dry eye, trabecular meshwork degeneration, and
ocular inflammation [9].
Analytical separation techniques have been used
extensively for BAK determination in pharmaceutical
products [1a,10] including high-performance liquid chro-
matography (HPLC) [2b,5,7a,11], ion chromatography
(IC) [12], capillary electrophoresis (CE) and fluorescence
[2b]. Electrochemical approaches provide rapid analysis
time and on-site monitoring compared to separation
methods. Electrochemical detection of BAK was achieved
using a phosphomolybdic acid modified carbon paste
electrode (CPE) [13]. Glassy carbon (GC), a mercury-
modified GC, and gold (Au) electrodes were used for the
trace determination of BAK in cosmetic and oral hygiene
products [14]. Of note is an electrochemical strategy using
a GC to study BAK’s physicochemical properties and
their effect on the de-chlorination of allyl chloride with a
detection limit of 2.2 mM [15].
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The boron-doped diamond (BDD) electrode offers a
wide potential range, and electrochemical stability with a
low background current. This study unravels the use of a
pristine BDD for the detection of four BAK compounds
in a non-aqueous medium. The method was then
extended to the detection of the C12 homolog in the
ophthalmic formulations. The results are corroborated by
HPLC coupled to ultraviolet (UV) detection. The electro-
chemical oxidation mechanism of BAK on the BDD
electrode is proposed. This method is simple and
straightforward over the method reported by Gabe et al.
[13], which requires the modification of the electrode, as
well as provides a lower limit of detection (LOD) than
the method of Muthuraman et al. [15].
2 Experimental Section
2.1 Chemicals
All chemicals of the highest purity were purchased from
Sigma-Aldrich (Dublin, Ireland). Three eye drops (Murine,
Optrex clear, and Optrex soothing) were obtained from a
local pharmacy in Cork, Ireland. These eye drops mainly
contain benzalkonium chloride, boric acid, borax, disodium
edetate, naphazoline hydrochloride, and purified water. A
certified reference material of BAK 50% (w/v) consists of
50.7% C12, 29.4% C14, 17.0% C16, and 2.8% C18 homologs
(Scheme 1). The supporting electrolyte consisting of 10 mM
tetrabutylammonium hexafluorophosphate (TBAH)/
acetonitrile (ACN) was utilized for the detection of BAK in
standard solutions and ophthalmic formulations. A BAK
stock solution (20 mg/mL) dissolved in ACN was diluted
with the supporting electrolyte to prepare the working
solutions with different concentrations.
2.2 Apparatus and Measurements
All electrochemical measurements were performed using
a CHI1040A electrochemical workstation (CH Instru-
ment, Austin, TX) equipped with an electrochemical cell
consisting of 3 electrodes: BDD (3 mm geometric diame-
ter, 0.1% doped boron, Windsor Scientific, Slough
Berkshire, UK)), a non-aqueous reference electrode (Ag/
Ag+, BASi), and a platinum (Pt) wire as a counter
electrode (Sigma-Aldrich, Dublin, Ireland). For compar-
ison, a glassy carbon (GC) electrode (3 mm geometric
diameter, BASi Analytical Instruments, West Lafayette,
IN) was obtained. Detailed information on instrumenta-
tion, electrode preparation can be found elsewhere [16].
Before measurement, the electrode was cleaned by
potential cycling from   1 to +2 V vs. Ag/Ag+ using
100 mV/s in 10 mM TBAH/ACN until a steady cyclic
voltammogram (CV) profile was attained.
2.3 High-performance Liquid Chromatography (HPLC)
The chromatographic analysis was performed on an Agilent
HPLC system [16] equipped with the Agilent ChemStation
software instrumental control and data acquisition. The
separation was performed on an Agilent poroshell 120
EC  C8 column (2.1×50 mm, 1.9 μm) using a gradient
mobile phase. All the BAK homologs exhibited the
maximum absorbance at 260 nm. The mobile phase compo-
sitions are A: 0.05% trifluoracetic acid (TFA) in H2O, B:
0.05% TFA in (ACN: isopropyl alcohol (IPA)), which was
filtered and sonicated before use. The column was equili-
brated for 20 min with the mobile phase before injection
with an injection volume of 1 μL. The BAK standard
solution and ophthalmic formulations were filtered (Econ-
ofltr Nylon, 13 mm, 0.2 μm) before analysis. Different
concentrations of BAK were prepared by diluting the BAK
stock solution in deionized water. The ophthalmic formula-
tions were used as received without dilution.
2.4 HPLC Method Validation
The proposed method was validated in terms of linear
range, linearity, sensitivity, inter-day, and intra-day pre-
cision. The detection linearity of BAK was established in
the range of 3 to 10 mg/mL in chromatographic analysis.
The intra-day (repeatability) was established by calculat-
ing the relative standard deviation (R.S.D %) for three
measurements at 3 mg/mL within one experiment of the
same day. The inter-day (intermediate precision) was
assessed by calculating three measurements at 3 mg/mL
within three experiments for three different days. Repeat-
ability and intermediate precision were calculated using
the retention time and oxidation potential for chromato-
graphic and electroanalysis, respectively.
3 Results and Discussion
3.1 Electrochemical Behavior of BAK
The CV presented only one irreversible oxidation peak at
+1.089 and at +1.54 V for GC and BDD electrodes,
respectively (Figure 1). The oxidation peak was also
broad as the standard BAK consisted of four different
BAK homologs, evincing their similar oxidation poten-
tials.
A series of experiments with square wave voltammetry
(SWV) was then conducted at the following optimal
parameters: amplitude (Esw) of 50 mV, a potential incre-
ment (ΔE) of 4 mV, and frequency (f) of 5 Hz (t=1/f, s).
SWV was conducted to obtain the lowest detection limitScheme 1. Structure of benzalkonium chloride homologs.
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for BAK. Compared to differential pulse voltammetry,
SWV provides higher sensitivity and thus it was chosen
for quantitation. The use of SWV indicated BAK
oxidation on the GC and BDD electrodes in the linear
range 4—80 μg/mL (Figure 2, 3) with an excellent correla-
tion coefficient (R2) of greater than 0.996 (Table 1). The
estimated detection limit (S/N=3) was 0.68 μg/mL and
0.4 μg/mL for the GC and BDD electrodes, respectively.
The reproducibility of the electrodes for BAK detection
was estimated from three repeated measurements with
40 μg/mL of BAK. The R.S.D % value of the potential
was 3.43% for GC and 0.4510% for BDD. Table 1
displays a comparison of analytical performance between
the BDD and GC electrode toward the BAK oxidation.
Compared to GC electrode, the BDD electrode exhibits
excellent sensitivity and repeatability, and high resistance
to fouling [17]. Consequently, BDD was selected for all
subsequent experiments to develop a chemosensor for
BAK homologs in the ophthalmic formulation.
The BDD electrode was also subject to cathodic treat-
ment to form an adsorption layer with hydrogen formation
(H-BDD), as opposed to the anodic treatment to form
reactive hydroxyl radicals (*OH) on the BDD surface
(BDD-*OH) [18]. The BDD electrode was treated with
0.5 M sulfuric acid at +3 V or   3 V for 30 min and detailed
information of such treatment is available elsewhere [19].
The anodic peak of BAK was observed at +1.794 V after
anodic treatment and at +1.652 V after cathodic treatment
and the response signal was slightly lower than that of bare
BDD (Figure S1). The effective surface area was calculated
using the Randles-Sevcik equation
Ip ¼ ð2:69� 10
5Þ n3=2 AD0
1=2 v1=2 c0*
where n is the number of electron transfer (n=1), A is
the effective surface area, D0 is the diffusion coefficient
(7.6×10  6 cm2s  1), v is the scan rate and c0* is the
concentration of K3[Fe (CN)6]. Cyclic voltammetry at
different scan rates (10—1000 mv/s) was performed using
the electrode immersed in a solution of 1 mMK3[Fe(CN)6]
in 0.1 MKCl. From the slope of the plot, Ip=ƒ(v
1/2) (figure
not shown) the effective surface areas of the bare, anodic
treated, and cathodic treated BDD were found to be
2.36×10  3, 0.83×10  3 and 2.25×10  3 cm2 respectively. The
surface area of the bare BDD was higher than that after
the treatments, which was attributed to the higher
response signal. Thus, the bare BDD electrode was used
for further experiments. The deconvolution of this broad
unsymmetrical peak resulted in three separated peaks at
1.54 V, 1.63 V, and 1.66 V, which could be assigned for
Fig. 1. CV response in the absence (black) and presence (red) of
80 μg/mL for BAK on the (a) GC and (b) BDD electrodes vs.
Ag/Ag+. Electrolyte: 10 mM TBAH/ACN with a scan rate
100 mV/s.
Fig. 2. SWVs of different BAK concentrations (4–80 μg/mL) at
(a) GC and (b) BDD electrodes vs. Ag/Ag+. Electrolyte:10 mM
TBAH/ACN and a scan rate 100 mV/s.
Fig. 3. Calibration plot of different BAK concentrations (4–80 μg/
mL) at (a) GC and (b) BDD electrodes vs. Ag/Ag+ in 10 mM
TBAH/ACN. The error bar was estimated from three different
values for each analyte concentration.
Table 1. Calibration plots and LOD using SWVat the GC and BDD electrodes.
Linear range (μg/mL) Linear regression equation






Glassy Carbon 4–80 y=0.0068 C
  0.0118
0.9973 3.43 0.68 μg/mL (1.7 μM)
Bare BDD 4–80 y=0.00135 C
+0.00299
0.9993 0.451 0.4 μg/mL
(1 μM)
a R.S.D (%) calculated from three SWV measurements for the potential at 40 μg/mL of BAK (n=3). b LOD (S/N=3).
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C12, C14, and combined C16–C18. The area of each peak over
the total broad peak area agreed well with their concen-
tration percentage in the standard mixture. Peak deconvo-
lution of the BAK standard mixture is shown in Figure 4.
The peak potential for irreversible systems normally
shifted toward positive potentials with increasing scan
rate (ν) [20], as shown in Figure 5a. A linear relationship
between the oxidation peak current and ν1/2 indicated e-
lectrode kinetics were diffusion-controlled (Figure 5b).
Such behavior is normally anticipated for the BDD
electrode, due to the low adsorption of analyte on the
electrode surface [20b, 21].
Despite that the exact mechanism of electrochemical
oxidation of BAK is not known, Aeromonas hydrophila
sp. K is capable of utilizing BAK as a sole source of
carbon and energy [22]. The initial attack on BAK is the
central fission of Calkyl-N bond by an oxygen-dependent
dehydrogenase to form an alkanal and benzyldimeth-
ylamine (BDMA) as shown in Scheme 2. Perhaps, this is a
general strategy of several microorganisms to gain access
to the alkyl chains of BAK [23]. The alkanal could be
oxidized to a corresponding acid via a beta-oxidation
pathway [23b]. A similar degradation pathway has been
proposed from the oxidation of BAK by S2O8
2  /Fe2+ [24].
In this context, this pathway for BAK is postulated for
electrochemical oxidation, considering the OH* radical, a
powerful reactive oxygen species (ROS) generated by the
BDD electrode. Of course, the exact mechanism of the
electrochemical oxidation of BAK by BDD is a subject of
future endeavors.
3.2 Electroanalysis of BAK in Ophthalmic Formulations
The optimal BDD method was applied to the determi-
nation of the BAK in three ophthalmic samples. A
representative SWV of a Murine ophthalmic sample
analyzed by the BDD is shown in Figure 6a whereas the
SWVs of Optrex Clear and Optrex are displayed in
Figure S2. The SWVs show only one peak around +1.5 V
Fig. 4. Resolved SWV of the standard mixture at 80 μg/mL of
BAK after the application of peak deconvolution using Origin
Pro 8.5.1. on the BDD electrode vs. Ag/Ag+ using 10 mM
TBAH/ACN.
Fig. 5. (a) CV responses with the varying scan rate from 10 to
1000 mV/s using 0.15 mg/mL of BAK in 10 mM TBAH/ACN. (b)
A linear relationship between Ip and ν1/2.
Scheme 2. A postulated electrochemical oxidation of BAK is
deciphered from the biodegradation of this compound by micro-
organisms or chemical oxidation [22].
Fig. 6. (a) SWVs of Murine ophthalmic solution and spiked with
40 μg/mL of BAK on the bare BDD electrode vs. Ag/Ag+ in
10 mM TBAH/ACN. (b) HPLC-UV gradient analysis of Murine
ophthalmic solution and spiked with 3 mg/mL of BAK analyzed
by gradient HPLC-UV. Mobile phase: A: 0.05% TFA in H2O, B:
0.05% TFA in (ACN: IPA; 50 :50), flow rate: 0.3 mL/min,
temperature 30 °C.
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because only C12 is present in the eye drops. The
estimated BAK concentration in the ophthalmic formula-
tions was 0.1 (0.01%), 0.051 (0.0051%), and 0.039
(0.0039%) mg/mL for Murine, Optrex Clear, and Optrex
Soothing, respectively (Table S1). The determined
amounts of BAK in the three samples were in agreement
with the labeled values of BAK by the manufacturers.
3.3 HPLC Analysis of BAK
HPLC equipped with a C8 column and UV-detection was
then conducted for the analysis of the BAK homologs in the
ophthalmic formulations. Initially, the gradient condition
was optimized with varying organic solvent composition and
analysis time (Figure S3–5). The calibration curves of four
homologs are presented in Figure S6 whereas Table S2
demonstrates the proportions of homologs in the BAK
standard solutions. The optimized HPLC-UV method was
then applied for the determination of BAK in three
different ophthalmic formulations. The HPLC data con-
firmed the presence of only the C12 homolog in the
ophthalmic formulations with the following corresponding
concentration (mg/mL): 0.097 (Murine) in Figure 6b, 0.047
(Optrex Clear), and 0.035 (Optrex Soothing) (Figure S7).
The content of BAK homologs in three ophthalmic
solutions is presented in Table S3. Such a result was not
completely unexpected as the C8 and C10 homologs have
very weak bactericidal activity. The C12 and C14 homologs
exhibit antibacterial effects at concentrations spanning 8—
400 μg/mL, and C12-benzalkonium chloride is the most
effective component of the BAK homologs [25]. The
Pharmacopoeia of Japan prescribes that BAK is composed
mainly of n-C12H25 and n-C14H29 homologs but no specific
amount of these two homologs are stipulated [25]. In the US
National Formulary XVI, the proportion of the C12 and C14
homologs must be over 40% and 20%, respectively [25].
The solubility and the critical micelle concentration of the
BAK homologs with carbon chain length above C14 is
extremely low [26]. Of importance is the binding to serum
albumin, as C14-BAK binds to serum albumin 2.5–3.7 times
more compared with C12-BAK. For a 10% solution of
human serum with 0.65% protein as albumin, about 70–
90% of C12-BAK with concentrations of 500–1000 μg/mL
remains unbound [25]. Despite all BAK homologs causing
cytotoxicity and corneal barrier dysfunction, the degree of
corneal toxicity has different concentration dependency
among the BAK homologs. C14-BAK (0.005%) damages
the epithelium, whereas C12-BAK has no effect at this
concentration [27]. Stronger concentrations are caustic and
damage the corneal endothelium irreversibly. In this con-
text, ophthalmic solutions are formulated only with the C12
homolog with the highest bactericidal activity and minimal
cytotoxicity. As a result, BAK is mostly used as a
preservative in eye drops with concentrations ranging from
0.004 to 0.01%, detectable at the BDD and by HPLC-UV
as reported earlier.
The analytical performance of the HPLC system for
baseline separation and detection of the BAK homologs is
summarized in Table S4. The regression coefficient (R2) of
four homologs was greater than 0.94. The repeatability was
in the range of 0.13–0.35% and intermediate precision in
the range of 0.30–0.75%, confirming the suitability of this
method for BAK determination. Electroanalysis of BAK by
BDD or even with GC offers better limits of detection,
compared with HPLC-UV detection (Tables 2, S5). How-
ever, the latter offers a baseline separation of 4 common
BAK homologs and identifies the presence of C12-BAK in
ophthalmic formulations. However, C12-BAK is commonly
formulated in ophthalmic solutions due to its low toxicity
and high bactericidal activity. Electroanalysis is sufficient for
the rapid and sensitive detection of this homolog in
ophthalmic formulations.
4 Conclusions
An efficient and simple method was described for
detecting BAK in ophthalmic formulations at the BDD
electrode. The rapid HPLC method confirmed the
presence of only the C12 homolog in three different eye
drops considering this homolog exhibits minimal cytotox-
icity with the highest bactericidal activity, compared to
other BAK homologs. The BDD electrode offers a lower
detection limit compared with HPLC-UV detection.
Ideally, an analytical method for BAK must differentiate
and quantitate the homologs in the BAK mixture with
C12, C14, and C16 as proportions of the alkyl groups. Thus,
HPLC equipped with a downstream BDD electrode may
be used for the separation and sensitive detection of BAK
Table 2. Comparison of the proposed method for the detection of BAK homologs on the BDD electrode and GC electrode with the literature
methods.















Carbon paste electrodes BAK 0.13×10  3–0.17 mM 0.9824 0.1 μM [13]
GC C16 0.01–0.48 mM N.R
a 2.2 mM [15]
a N.R, not reported
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homologs, formulated in pharmaceutical preparations
[16]. If necessary, the electrode can be coated with Nafion
[28], a negatively charged polymer to enhance the
selective adsorption of BAK homologs. In this context,
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